PWM
ADCT icon

Palumbo Wealth Management’s ADC Therapeutics ADCT Stock Holding History

Palumbo Wealth Management’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,270
Closed -$41.9K – 161
2024
Q2 		$41.9K Buy
+13,270
New +$52.7K 0.02% 147

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Palumbo Wealth Management's ADCT Position: Q3 2024 in Review

Palumbo Wealth Management sold out of ADC Therapeutics (ADCT) in Q3 2024, closing a stake of 13,270 shares — an estimated $41.9K sold.

Palumbo Wealth Management first reported a position in ADCT in Q2 2024 and held it in 1 quarter. The position peaked at $41.9K in Q2 2024. 77 funds tracked by Wall St. Rank hold ADCT as of Q3 2024.

  • Palumbo Wealth Management reported no remaining ADC Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Palumbo Wealth Management sold 13,270 ADC Therapeutics shares in Q3 2024, an estimated $41.9K.
  • Palumbo Wealth Management first reported a position in ADC Therapeutics in Q2 2024 and held it in 1 quarter.
  • Palumbo Wealth Management's ADC Therapeutics position peaked at $41.9K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2024.

Based on Palumbo Wealth Management's 13F filing for Q3 2024, filed 28 Oct 2024.